Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Similarity Study of NKF-INS(G), US-Lantus, and EU-Lantus in Healthy Volunteers
NCT06627478Phase 1Completed
- Sponsor
- Xentria
- Start
- Oct 2024
- Primary completion
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin glargine in diabetes mellitus (DM) (3 arms), sponsored by Xentria. Primary endpoint: Area Under the M1 Concentration-Time Curve From 0 to 12 Hours. Started Oct 2024; status: completed.
02
Drugs
insulin glargine
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT06627478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06627478.